1. Scrip
  2. >>Business
  3. >>Strategy

BMS’ Boerner Bets On AI-Driven R&D In India, Points To Potential For MS, Lupus Drugs

Hyderabad Largest Ex-US Site By 2025

 
• By Vibha Ravi

Bristol Myers Squibb CEO Christopher Boerner is looking to India to house the the company’s largest R&D site outside of the US, channeling the country's IT expertise to expand its AI-driven small-molecule research. He also wants to bring its drugs to treat multiple sclerosis and Lupus to India.

BM CEO Christopher Boerner at BioAsia
At BioAsia (L to R) - BMS CEO Christopher Boerner, Telangana Minister For Industries & Commerce Dudilla S Babu, Telangana Chief Minister Anumula R Reddy, Western Australia Minister of Health Amber-Jade Sanderson, Nobel Laureate Prof. Gregg Semenza • Source: BioAsia, Government of Telangana

Bristol Myers Squibb Company CEO Christopher Boerner certainly made the job for company recruiters in India easier when he spoke of plans to make its Hyderabad R&D centre the largest one outside of the US as early as next year and pointed to the country’s innovation potential in a powerful, spirited keynote address at a recent event in the country.

With the advent of artificial intelligence (AI)-led drug development, it’s felt that India could leapfrog a few stages to establish an advantage in an area of the drug discovery process requiring

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.